MediPrint Ophthalmics Presents Promising Results from Phase 2b Clinical Trial of LL-BMT1 for Glaucoma at American Academy of Optometry

INDIANAPOLIS--(BUSINESS WIRE)-- #clinicaltrial--MediPrint® Ophthalmics (MediPrint), a clinical-stage ophthalmic drug delivery company based in San Diego, announced the results of the Company’s Phase 2b clinical trial of LL-BMT1. Employing a novel 3D printed, drug-eluting contact lens for sustained delivery of bimatoprost and hyaluronic acid, the clinical trial achieved all Phase 2b endpoints. In a presentation by Dr. Ian Ben Gaddie at the American Academy of Optometry’s annual meeting in Indianapolis, the resul